111 related articles for article (PubMed ID: 31156017)
1. Prostate cancer incidence and diagnosis in men with PSA levels >20 ng/ml: is it possible to decrease the number of biopsy cores?
Ozorak A; Zumrutbas AE; Bingol G; Ozlulerden Y; Ozturk SA
Aging Male; 2020 Dec; 23(5):893-900. PubMed ID: 31156017
[TBL] [Abstract][Full Text] [Related]
2. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
Dell'Atti L
J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
[TBL] [Abstract][Full Text] [Related]
3. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.
Schröder FH; Roobol-Bouts M; Vis AN; van der Kwast T; Kranse R
Urology; 2001 Jan; 57(1):83-90. PubMed ID: 11164149
[TBL] [Abstract][Full Text] [Related]
5. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.
Pepe P; Aragona F
Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):316-9. PubMed ID: 20714341
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome of transrectal ultrasound-guided prostate biopsy, targeting eight cores, for detecting prostate cancer in Japanese men.
Ishimura T; Sakai I; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):47-50. PubMed ID: 15162826
[TBL] [Abstract][Full Text] [Related]
7. Role of transperineal six-core prostate biopsy in patients with prostate-specific antigen level greater than 10 ng/mL and abnormal digital rectal examination findings.
Luciani LG; De Giorgi G; Valotto C; Zanin M; Bierti S; Zattoni F
Urology; 2006 Mar; 67(3):555-8. PubMed ID: 16527579
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of transrectal ultrasound-guided prostate biopsy in men younger than 50 years old with an elevated prostate-specific antigen concentration (>4.0 ng/mL).
Lu CH; Lin TP; Shen SH; Huang YH; Chung HJ; Kuo JY; Huang WJS; Wu HHH; Chang YH; Lin ATL; Chen KK
J Chin Med Assoc; 2017 Jul; 80(7):413-418. PubMed ID: 28529023
[TBL] [Abstract][Full Text] [Related]
9. Value of prostate-specific antigen (PSA) mass ratio in the detection of prostate cancer in men with PSA levels of ≤10 ng/mL.
Hong SK; Oh JJ; Byun SS; Hwang SI; Choo MS; Lee SE
BJU Int; 2012 Jul; 110(2 Pt 2):E81-5. PubMed ID: 22093144
[TBL] [Abstract][Full Text] [Related]
10. Prostate gland volume is a strong predictor of biopsy results in men 70 years or older with prostate-specific antigen levels of 2.0-10.0 ng/mL.
Kobayashi T; Mitsumori K; Kawahara T; Nishizawa K; Ogura K; Ide Y
Int J Urol; 2005 Nov; 12(11):969-75. PubMed ID: 16351653
[TBL] [Abstract][Full Text] [Related]
11. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
12. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.
Horninger W; Cheli CD; Babaian RJ; Fritsche HA; Lepor H; Taneja SS; Childs S; Stamey TA; Sokoll LJ; Chan DW; Brawer MK; Partin AW; Bartsch G
Urology; 2002 Oct; 60(4 Suppl 1):31-5. PubMed ID: 12384160
[TBL] [Abstract][Full Text] [Related]
13. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.
Babaian RJ; Johnston DA; Naccarato W; Ayala A; Bhadkamkar VA; Fritsche HA HA
J Urol; 2001 Mar; 165(3):757-60. PubMed ID: 11176461
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer diagnosis: should patients with prostate specific antigen >10ng/mL have stratified prostate biopsy protocols?
Philip J; Manikandan R; Javlé P; Foster CS
Cancer Detect Prev; 2009; 32(4):314-8. PubMed ID: 19193497
[TBL] [Abstract][Full Text] [Related]
15. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
[TBL] [Abstract][Full Text] [Related]
16. PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.
Kaplan SA; Ghafar MA; Volpe MA; Lam JS; Fromer D; Te AE
Urology; 2002 Sep; 60(3):464-8. PubMed ID: 12350485
[TBL] [Abstract][Full Text] [Related]
17. The value of free and total prostate specific antigen in identifying patients for prostatic biopsy and its relationship to Gleason score and number of positive cores.
Bulbul MA; Khauli RB; Nasr R; Hemady K; Wazzan W
J Med Liban; 2000; 48(2):59-62. PubMed ID: 11028151
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
[TBL] [Abstract][Full Text] [Related]
19. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
20. Anterior apical cores in the initial prostate biopsy does not increase detection of significant prostate cancer.
Ekin RG; Zorlu F; Akarken I; Yildirim Z; Tarhan H; Koc G; Kucuk U; Bayol U
Urol J; 2015 Apr; 12(2):2084-9. PubMed ID: 25923153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
